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Abstract
Introduction UDP-glucuronosyltransferase (UGT) and
sulfotransferase (SULT) enzymes are involved in removing sex
hormones from circulation. Polymorphic variation in five UGT
and  SULT  genes – UGT1A1  ((TA)6/(TA)7),  UGT2B4
(Asp458Glu), UGT2B7 (His268Tyr), UGT2B15 (Asp85Tyr), and
SULT1A1 (Arg213His) – may be associated with circulating sex
hormone concentrations, or the risk of an estrogen receptor-
negative (ER-) or progesterone receptor-negative (PR-) tumor.
Methods Logistic regression analysis was used to estimate the
odds ratios of an ER-  or PR-  tumor associated with
polymorphisms in the genes listed above for 163 breast cancer
patients from a population-based cohort study of women in
western Washington. Adjusted geometric mean estradiol,
estrone, and testosterone concentrations were calculated within
each  UGT  and  SULT  genotype for a subpopulation of
postmenopausal breast cancer patients not on hormone therapy
2–3 years after diagnosis (n = 89).
Results The variant allele of UGT1A1  was associated with
reduced risk of an ER- tumor (P for trend = 0.03), and variants
of  UGT2B15  and  SULT1A1  were associated with non-
statistically significant risk reductions. There was some
indication that plasma estradiol and testosterone concentrations
varied by UGT2B15 and SULT1A1 genotypes; women with the
UGT2B15  Asp/Tyr and Tyr/Tyr genotypes had higher
concentrations of estradiol than women with the Asp/Asp
genotype (P  = 0.004). Compared with women with the
SULT1A1 Arg/Arg and Arg/His genotypes, women with the His/
His genotype had elevated concentrations of testosterone (P =
0.003).
Conclusions The risk of ER- breast cancer tumors may vary by
UGT  or  SULT  genotype. Further, plasma estradiol and
testosterone concentrations in breast cancer patients may differ
depending on some UGT and SULT genotypes.
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Introduction
Exposure to increased concentrations of both estrogens
and androgens has been implicated in the development of
breast cancer [1-3]. There are varied mechanisms by which
sex hormones might act to propagate malignancy; at the
same time, there are only a few pathways by which these
hormones are inactivated and removed from circulation.
Glucuronidation and sulfonation are two of the pathways
through which sex hormones can be metabolized to inac-
tive compounds [4-6].
Glucuronidation is catalyzed by UDP-glucuronosyltrans-
ferase (UGT) enzymes and involves the covalent addition of
glucuronic acid, resulting in more hydrophilic compounds
CI = confidence interval; CV = coefficient of variation; ER = estrogen receptor; HEAL = Health, Eating, Activity, and Lifestyle; OR = odds ratio; PR 
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that are excreted from the body via urine or bile [6,7].
UGT1A1, UGT2B4, UGT2B7, and UGT2B15 are among
the UGT enzymes that metabolize steroid hormones [4].
The UGT1A1 protein glucuronidates estriol, 17β-estradiol,
ethinylestradiol, and catechol estrogens [8-11]. Variation in
glucuronidation between individuals is due primarily to a
variable number of TA repeats in the A(TA)nTAA (n = 5–8)
promoter sequence in the TATA-box region [12,13].
Among the variant alleles, (TA)7 (the most common variant)
and (TA)8 are associated with lower transcriptional activity
in vitro than the (TA)6 wild-type allele [12-14]. An increas-
ing number of TA repeats has been associated with
increased breast cancer risk in premenopausal African-
American women, but not postmenopausal African-Ameri-
can or premenopausal or postmenopausal Caucasian
women [14,15].
The UGT2B4 enzyme glucuronidates catechol estrogens,
estriol, and bile acids [16-18]. A polymorphism in the
UGT2B4 gene (Asp458Glu) has been reported [16]. The
two alleles have similar tissue distributions and currently
there is little biochemical evidence to suggest different sub-
strate specificities between the two isoforms [16,19]. How-
ever, it has not yet been determined whether this
polymorphism affects UGT2B4 protein function through
other mechanisms. The UGT2B7 enzyme glucuronidates a
wide variety of steroids, including catechol estrogens,
estriol, and hydroxylated androgens [10,17,18,20-25]. A
polymorphism in the UGT2B7 gene results in an amino
acid change (His268Tyr) [22], possibly near the proposed
substrate-binding site of the protein [22,26]. The two alle-
les seem to have similar enzymatic activities for most sub-
strates [10,24,27], with the possible exception of
androsterone, estriol, and estradiol [21-23,25]. The
UGT2B15 enzyme conjugates catechol estrogens and the
C19 sex steroids testosterone, dihydrotestosterone, and
androstane-3α, 17β-diol [18,28-30]. A polymorphism in
the UGT2B15 gene (Asp85Tyr) [28] results in an allele with
a Vmax for androstane-3α, 17β-diol and dihydrotestosterone
in vitro that is double that of the aspartic acid allele [28].
Sulfotransferases (SULTs) comprise another group of
enzymes involved in the removal of circulating bioactive sex
hormones. The SULT1A1 enzyme can catalyze the sulfona-
tion of estrogens to form inactive estrogen sulfates
[6,31,32]. It has been proposed that estrone sulfate serves
as an inactive reservoir in the blood from which estrone and
estradiol can be regenerated [6,33]. A polymorphism in the
SULT1A1 gene (Arg213His) has been identified [34]. Indi-
viduals homozygous for the histidine allele have lower plate-
let SULT activity in vitro than wild-type and heterozygous
individuals [34,35]. Further, the SULT1A1 variant allele is
associated with an elevated breast cancer risk among post-
menopausal women [36].
Because the UGT and SULT enzymes are important in the
inactivation and removal of bioactive sex hormones from
target tissues, investigating the association between poly-
morphisms in these genes and circulating sex hormone
concentrations might help to elucidate the potential func-
tional relevance of these polymorphisms in vivo. These
observations might support experimental results suggest-
ing a functional role for polymorphisms in UGT1A1,
UGT2B15, and SULT1A1, or might generate new hypoth-
eses about the potential effect of sequence variations in
UGT2B4 and UGT2B7, for which there is relatively little
biochemical evidence suggesting a functional effect in
vitro. With this purpose we investigated the association
between these polymorphisms and circulating sex hor-
mone concentrations in postmenopausal breast cancer
patients not taking hormones 2–3 years after diagnosis. In
view of increasing evidence that hormones are important in
the development of hormone-dependent and hormone-
independent breast cancer tumors [37-41], we also exam-
ined the association between polymorphisms in the
UGT1A1, UGT2B4, UGT2B7, UGT2B15, and SULT1A1
genes and breast tumor estrogen receptor (ER) and pro-
gesterone receptor (PR) status in newly diagnosed breast
cancer patients.
Materials and methods
Study population
The Health, Eating, Activity, and Lifestyle (HEAL) study is a
population-based, multicenter prospective cohort study in
which women with breast cancer are followed to determine
whether breast cancer prognosis is associated with diet,
physical activity, sex hormones, weight, or other exposures
[42]. Participants in the HEAL study were identified
through Surveillance, Epidemiology, and End Results
(SEER) registries in western Washington state, in New
Mexico, and in Los Angeles County, California. The analy-
ses presented here are limited to breast cancer cases in
Washington state who were identified through the western
Washington SEER cancer registry between 1996 and
1999. To be eligible, women had to be newly diagnosed
with stage 0, I, II, or IIIa breast cancer, living in King, Pierce,
or Snohomish counties, and to have clinic measurements
a n d  a  b l o o d  d r a w  w i t h i n  4  t o  1 2  m o n t h s  o f  d i a g n o s i s .
Because the majority of women were either Caucasian or
Asian, the analyses were restricted to these two races. Of
202 patients interviewed in western Washington, 184
women were Caucasian or Asian and had a blood draw at
baseline. Of these women, the ER and PR status of the
breast tumor was determined for 163 women. Women for
whom ER and PR status were determined did not signifi-
cantly differ from the 21 women with unknown receptor sta-
tus with respect to characteristics presented in Table 1,
with the exception that the latter women were more likely to
have in situ breast cancer (31% versus 52%). A partici-
pant's menopausal status was determined by using self-Available online http://breast-cancer-research.com/content/6/5/R488
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Table 1
Selected characteristics of the Caucasian and Asian women enrolled in the Health, Eating, Activity, and Lifestyle study and 
asubpopulation used for investigating associations with circulating sex hormones at the 24-month follow-up
Characteristic Baseline (n = 163) Subpopulation at 24-month follow-upa (n = 89)
n (%) n (%)
Age at enrollment, years 52.4 (6.5)b 57.3 (5.7)b
40–49 59 (36) 10 (11)
50–59 75 (46) 43 (48)
60–69 29 (18) 36 (40)
Race
Caucasian 150 (92) 82 (92)
Asian 13 (8) 7 (8)
Number of pregnancies
lasting at least 6 months n/a
0 31 (19)
1 27 (17)
2 59 (36)
3+ 45 (28)
Weight change since age 18 (kg) +15.8 (14.4)b n/a
Body fat (%) n/a 36.8 (5.5)b
Tumor receptor status
ER+ tumor 124 (76) n/a
PR+ tumor 128 (79) n/a
ER+/PR+ tumor 107 (66) n/a
ER+/PR tumor 17 (10)
ER /PR+ tumor 21 (13)
ER /PR tumor 18 (11)
Stage of disease
0, in situ 51 (31) n/a
I 83 (51)
II 29 (18)
Subject genotypes
UGT1A1 genotypes (TA)6/(TA)7
(TA)6/(TA)6 80 (49) 49 (55)
(TA)6/(TA)7 72 (44) 36 (40)
(TA)7/(TA)7 11 (7) 4 (5)
(TA)7 allele frequency 0.29 0.25
UGT2B4 genotypes (Asp458Glu)
Asp/Asp 104 (64) 53 (60)
Asp/Glu 46 (28) 29 (33)
Glu/Glu 13 (8) 7 (8)
Glu allele frequency 0.22 0.24Breast Cancer Research    Vol 6 No 5    Sparks et al.
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reported information on estrogen and tamoxifen use, prior
ovarian surgery or hysterectomy, menstrual history, and
measured values of estrone, estradiol, and follicle-stimulat-
ing hormone. At baseline, 61 women were classified as
premenopausal, 98 as postmenopausal and 4 were unable
to be classified. Data from a follow-up interview and blood
draw that occurred 24 months after initial enrollment were
used for the analysis of serum hormone concentrations. At
the 24-month follow-up, 35 women were classified as pre-
menopausal, 114 as postmenopausal, and 16 were unable
to be classified. Because we were unable to collect blood
samples from premenopausal women at the same point in
the menstrual cycle, hormone analyses were limited to
postmenopausal Caucasian and Asian women who had
complete data for estrone, estradiol, height and weight, and
who were not taking estrogen or progesterone replace-
ment hormones at the time of the blood draw (n = 89).
There was no correlation between hormone concentrations
and time from breast cancer diagnosis to blood draw at the
24-month follow-up.
Written informed consent was obtained from each partici-
pant. The protocol was approved by the Institutional
Review Board of the Fred Hutchinson Cancer Research
Center.
Data collection
Data from two time points were used in this study. The first
time point was the time of study enrollment, 4–12 months
after breast cancer diagnosis. The second time point was
about 24 months after study enrollment. Patients were
mailed study questionnaires to complete and bring with
them to their clinic evaluations at the Fred Hutchinson Can-
cer Research Center Prevention Studies Clinic. Information
was collected on the following: dietary intake; health habits;
reproductive and menstrual history; history of use of oral
contraceptives and hormone replacement therapy; medical
history, including history of endocrine problems and other
medical problems; history of benign breast disease; family
history of breast cancer, other cancers, and diabetes melli-
tus; history of tobacco, caffeine, and alcohol use; lifetime
weight patterns; detailed current and pre-diagnostic physi-
cal activity habits; mammographic screening; and selected
demographic data. Standard height and weight measure-
ments were obtained by trained staff during home or clinic
visits. Percentage body fat was measured by bioelectric
impedance (RJL Multifrequency Bioelectric Impedance
Analyzer, Clinton Township, MI). Bioelectrical impedance
measurements were made with standard electrode place-
ments after a minimum 4-hour fast.
Hormone assays
A 30 ml fasting blood draw was collected at the 24-month
follow-up visit to determine circulating concentrations of
sex hormones. Blood was processed within 1 hour of col-
lection; serum, plasma, and buffy coat aliquots were stored
at -70 to -80°C. Dates of sample collection and processing,
UGT2B7 genotypes (His268Tyr)
His/His 41 (25) 24 (27)
His/Tyr 73 (45) 48 (54)
Tyr/Tyr 49 (30) 17 (19)
Tyr allele frequency 0.52 0.46
UGT2B15 genotypes (Asp85Tyr)
Asp/Asp 32 (20) 19 (21)
Asp/Tyr 83 (51) 47 (53)
Tyr/Tyr 48 (29) 23 (26)
Tyr allele frequency 0.55 0.52
SULT1A1 genotypes (Arg213His)
Arg/Arg 71 (43) 39 (44)
Arg/His 68 (42) 38 (43)
His/His 24 (15) 12 (13)
His allele frequency 0.36 0.35
ER, estrogen receptor; n/a, not applicable; PR, progesterone receptor. aRestricted to postmenopausal women not taking estrogen or 
progesterone therapy at the time of blood draw for investigation of associations between genotype and sex hormone concentrations. bMean (SD).
Table 1 (Continued)
Selected characteristics of the Caucasian and Asian women enrolled in the Health, Eating, Activity, and Lifestyle study and 
asubpopulation used for investigating associations with circulating sex hormones at the 24-month follow-upAvailable online http://breast-cancer-research.com/content/6/5/R488
R492
time of day of blood collection, and time since last meal
were recorded.
Estrone and estradiol assays were performed at Quest
Diagnostics Nichols Institute (San Juan Capistrano, CA)
between July and August 2001. The testosterone assay
was performed in Dr Frank Stanczyk's laboratory at the Uni-
versity of Southern California between April and June
2002. Samples were assigned randomly to assay batches
and ordered randomly within each batch. Laboratory per-
sonnel performing the assays were blinded to subject
identity.
Estrone and estradiol assay methods consisted of organic
solvent extraction, followed by Celite column partition chro-
matography before quantification by radioimmunoassay.
The reported sensitivities of these assays are less than 10
pg/ml and less than 2 pg/ml, respectively. Testosterone
was also measured by extraction, Celite column chroma-
tography, and radioimmunoassay; this method has a sensi-
tivity of 1 ng/dl. Twenty replicated samples and eight
pooled quality-control samples (two samples per batch)
were included in the estrone and estradiol blood assays.
For estrone and estradiol, the intra-assay coefficients of
variation (CVs) were 13.3% and 28.8%, respectively, and
the total CV results were 13.3% and 29.1%, respectively.
For testosterone, 20 replicated samples and 14 pooled
quality-control samples (two samples per batch) were
included in the blood assays. The intra-assay CV and total
CV were both 9.6%. Four subjects had estrone measure-
ments below the 10 pg/ml limit of detection. To calculate a
representative estrone value for measurements below this
detection limit, we fitted a truncated log-normal distribution
to the observed estrone data. The truncation was consid-
ered at the lower end of the distribution and the cumulative
proportion at the truncation point (namely, estrone = 10 pg/
ml) was used as the likelihood contribution from each of the
subjects with estrone below the detection limit. The maxi-
mum likelihood estimate of the mean of the lognormal dis-
tribution was 3.079 and that of the standard deviation was
0.453. Using these maximum likelihood estimates in the
lognormal distribution, we calculated the mean estrone
value less than 10 pg/ml to be 8.702 pg/ml. The four
estrone measurements below the limit of detection were
assigned this value.
Hormone receptor characterization
Paraffin-embedded breast tumor tissue samples from 163
women were tested for this study. ER and PR proteins were
assessed by immunohistochemistry in a single laboratory
without knowledge of other laboratory results, patient char-
acteristics, or outcome. Tissue blocks were selected by
reviewing all histologic slides for each case. Blocks for test-
ing were selected for the presence of representative tumor
and, when available, the presence of adjacent benign epi-
thelium (used as an internal positive control). Immunohisto-
chemistry was performed with modified standard
immunohistochemical techniques. In brief, 5 µm sections of
tumor were cut onto glass slides and blocked for endog-
enous peroxidase. Slides were treated with microwaves in
the presence of citrate buffer [43-45]. After washes, pri-
mary antibodies (monoclonal anti-PR clone 1A6 [NovoCas-
tra Lab] [46,47] and monoclonal anti-ER clone ER1D5
[AMAC, Inc.]) [48-50] were applied to the sections and
incubated for 1 hour. Slides were washed and appropriate
biotinylated secondary antibody, diluted in accordance with
the manufacturer's instructions (Vector Laboratories, Burl-
ingame, CA), was applied for 30 minutes. Slides were incu-
bated for 30 minutes with avidin–biotin complex, followed
by diaminobenzidine with 8% NiCl2 for 10 minutes; nuclei
were counterstained with methyl green [51,52]. Tumor
cells were scored positive if nuclear immunostaining was
present and more than 5% of tumor cells had positive
staining.
Genotyping
A 50 ml fasting blood draw was collected at the time of the
baseline interview. Blood was processed into serum,
plasma, and buffy coat fractions and aliquots were stored
at -70 to -80°C. DNA for genotyping was extracted from the
buffy coat fraction at the Core Specimen Processing Lab-
oratory (Fred Hutchinson Cancer Research Center) with
standard techniques.
SULT1A1 genotyping of the Arg213His polymorphism was
performed with a restriction-fragment-length polymorphism
assay. A SULT1A1-specific fragment containing the poly-
morphism was amplified in a 20 µl reaction containing 1 ×
GeneAmp buffer II (Applied Biosystems, Foster City, CA),
3 mM MgCl2, 200 µM deoxynucleotide triphosphates, each
primer at 200 nM (forward primer 5'-AGTTGGCTCT-
GCAGGGTTTCT-3', reverse primer 5'-ACCACGAAGTC-
CACGGTCTC-3'), 100 ng of genomic DNA, and 0.5 U of
AmpliTaq DNA polymerase (Applied Biosystems). Cycling
was as follows: initial denaturation at 94°C for 5 minutes,
followed by 35 cycles of 94°C for 30 seconds, 59°C for 45
seconds, and 72°C for 45 seconds, and final extension at
72°C for 5 minutes. The amplified fragment was digested
with HhaI and separated on a 2% NuSieve agarose gel
(Cambrex, Rockland, ME). The fragment sizes were 160
and 40 base pairs for the wild-type allele, and 200 base
pairs for the variant allele. For quality control purposes, gen-
otyping was repeated for 10% of the samples for each gen-
otype. There were no discrepancies between the two
results.  UGT2B4  Asp458Glu,  UGT2B7  His268Tyr,
UGT2B15 Asp85Tyr, and UGT1A1 [TA]n genotyping was
performed as described previously [53,54].Breast Cancer Research    Vol 6 No 5    Sparks et al.
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Statistical methods
We addressed two separate research questions, using two
different statistical models. We first examined whether gen-
otype was related to the risk of developing an ER-negative
(ER-) or PR-negative (PR-) breast cancer tumor. Odds
ratios (ORs) and 95% confidence intervals (95% CIs) were
calculated by using unconditional logistic regression analy-
sis to evaluate the association between genotype and
tumor receptor status. We adjusted our logistic regression
analyses for variables for which we had a priori knowledge
of potential contribution to breast cancer risk or to the
development of hormone-dependent or hormone-inde-
pendent breast tumors. Because of the small size of the
study, the data were not sufficiently robust to employ spe-
cific methods to evaluate confounding. In addition to race
(Caucasian/Asian), the following breast cancer risk factors
were included as covariates in the analysis: age at the time
of interview (continuous), age at menarche (continuous),
number of ovaries remaining, number of pregnancies last-
ing at least 6 months (0, 1, 2, or 3 or more), menopausal
status at time of baseline interview (premenopausal/post-
menopausal), smoker at time of interview (yes/no), parity/
age at first birth (nulliparous, age at first birth 26 or less,
age at first birth more than 26), change in weight from age
18 to the age that the subject had most recently passed
(35, 50, or 60 years old). Eight of the 163 women were
excluded from the logistic regression analyses because of
missing covariate data, leaving 155 women in the final
model. Genotype indicator variables were created by using
the wild-type genotype as the reference category in the
regression models. Genotypes were also evaluated with
dichotomous variables ('any wild-type allele' [wild-type and
heterozygous individuals] versus homozygous variant indi-
viduals, and 'any variant allele' [heterozygous and
homozygous variant individuals] versus wild-type individu-
als) when patterns suggested a dominant or recessive gen-
otype effect, respectively. We evaluated menopausal
status as a potential effect modifier but were unable to eval-
uate effect modification by race owing to small numbers.
However, we modeled effects excluding Asian women to
evaluate whether results were different when limited to
Caucasian women. All logistic regression analyses were
performed with SAS statistical software, version 8.2 (SAS
Institute, Cary, NC).
Our second research question examined whether geno-
type was related to sex hormone concentrations. Linear
regression analysis with robust variance estimates was
used to evaluate the association between UGT and SULT
genotypes and circulating sex hormone concentrations
(estrone, estradiol, testosterone) in postmenopausal
women not taking estrogen or progesterone replacement
hormones at the time of the blood draw. Hormone concen-
trations were natural-logarithm transformed to approximate
normal distributions. We adjusted the linear regression
analyses for variables for which we had a priori knowledge
of potential contribution to sex hormone concentrations.
Geometric mean hormone concentrations within each gen-
otype were calculated after adjustment for age at the time
of interview (continuous), percentage body fat (continu-
ous), tamoxifen use at the time of blood draw (yes/no), alco-
hol use (yes/no), smoking (yes/no), number of ovaries
remaining, race (Asian/Caucasian), and batch number
(estrone and estradiol only). We evaluated tamoxifen use
as a potential effect modifier. As with the logistic regression
analyses, we evaluated whether restriction to Caucasian
women altered the results. Of the 82 Caucasian and 7
Asian postmenopausal women with complete data for
estrone, estradiol, height, and weight who were not taking
estrogen or progesterone replacement hormones at the
time of the blood draw, two were lacking body fat data and
one was lacking data for plasma testosterone. These
women were dropped from the multivariate linear regres-
sion analysis, resulting in 87 women with estradiol and
estrone data, and 86 women with testosterone data. All lin-
ear regression analyses were performed with Stata statisti-
cal software, version 7 (Stata Corporation, College Station,
TX).
Results
A total of 163 women (150 Caucasian and 13 Asian) from
Washington state were enrolled in the HEAL study and had
complete baseline interview and hormone receptor data.
Most women were diagnosed with Stage I breast cancer
(51%) (Table 1), were postmenopausal at the time of study
enrollment (60%), and had no known family history of
breast cancer (51%). Most of these women had an ER-
positive (ER+) or PR-positive (PR+) breast tumor and 66%
had a combined ER+/PR+ tumor.
In Caucasians (n = 150), the observed variant allele fre-
quencies of each gene were as follows: UGT1A1, (TA)7 =
0.31; UGT2B4, Glu458 = 0.24; UGT2B7, Tyr268 = 0.55;
UGT2B15, Tyr85 = 0.56; SULT1A1, His213 = 0.38. These
allele frequencies were similar to those in Caucasians in
previous reports [13,34,53-56]. We did not calculate sep-
arate allele frequencies in Asians because of the small
number of individuals (n = 13). In Caucasians, genotype
frequencies for each gene did not deviate from Hardy–
Weinberg equilibrium.
As shown in Table 2, the risk of an ER- breast tumor
seemed smaller for individuals with the UGT1A1 variant
allele (compared with (TA)6/(TA)6: OR (TA)6/(TA)7 = 0.6,
95% CI 0.2–1.3; OR (TA)7/(TA)7 = 0.0, 95% CI 0.0–0.5;
P for trend = 0.03). Further, a reduced risk of an ER- tumor
might be associated with the SULT1A1 variant allele (OR
= 0.6, 95% CI 0.3–1.2) and the UGT2B15 homozygous
variant genotype (OR = 0.4, 95% CI 0.1–1.2). The effects
were similar when the sample was limited to CaucasianAvailable online http://breast-cancer-research.com/content/6/5/R488
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women (data not shown). Trends for UGT1A1, UGT2B7,
UGT2B15, and SULT1A1 were generally similar among
premenopausal and postmenopausal women (data not
shown).
Among the subpopulation of women eligible for hormone
analysis (n  = 89; Table 1), most (62%) were taking
tamoxifen, but very few were current smokers (n  = 4).
Among this subgroup, women with the UGT1A1  (TA)7/
(TA)7 genotype had 58% higher geometric mean estradiol
concentrations (P = 0.01) than women with the (TA)6/(TA)6
wild-type genotype (Table 3) and 71% higher geometric
mean estradiol concentrations (P = 0.002) than the com-
bined group of women with either the (TA)6/(TA)6 or the
(TA)6/(TA)7 genotype (9.8 pg/ml, 95% CI 8.7–11.1 versus
16.8 pg/ml, 95% CI 12.6–22.5). Women with the
UGT2B15 Asp/Tyr and Tyr/Tyr genotypes had 59% (P =
0.003) and 44% (P = 0.05) higher geometric mean estra-
diol concentrations than women with the Asp/Asp geno-
type, respectively (Table 3). When genotypes were
combined, women with any Tyr85 allele had 53% higher
geometric mean estradiol concentrations than Asp/Asp
wild-type women with no Tyr85 allele (P = 0.004; 7.2 pg/ml,
95% CI 5.6–9.4 versus 11.1 pg/ml, 95% CI 9.8–12.5).
Finally, women with the SULT1A1 His/His genotype had
32% higher geometric mean testosterone concentrations
than women with the wild-type Arg/Arg genotype (P  =
0.03; Table 3), and 39% higher geometric mean testoster-
one concentrations than the combined group of women
with the Arg/Arg or Arg/His genotype (P = 0.003; 26.4 ng/
dl, 95% CI 24.3–28.7 versus 36.8 ng/dl, 95% CI 30.5–
44.3). No statistically significant associations were
observed between estradiol, estrone or testosterone con-
centrations and UGT2B4 or UGT2B7 genotypes. Results
Table 2
UGT1A1, UGT2B4, UGT2B7, UBT2B15, and SULT1A1 genotypes and risk of ER- and PR- breast tumors in Caucasian and Asian female 
breast cancer patients, Washington state
Gene ER+
n
ER-
n
ORa 
ER-tumor
Combinedb PR+
n
PR-
n
ORa 
PR-tumor
Combinedb
UGT1A1
(TA)6/(TA)6 53 21 1.0 (ref) 1.0 (ref) 57 17 1.0 (ref) 1.0 (ref)e
(TA)6/(TA)7 55 16 0.6 (0.2–1.3) 55 16 1.1 (0.5–2.6)
(TA)7/(TA)7 10 0 0.0 (0.0–0.5)* 0.5 (0.2–1.1)d 9 1 0.3 (0.02–2.6) 0.2 (0.02–2.4)
UGT2B4
Asp/Asp 78 21 1.0 (ref) 1.0 (ref) 81 18 1.0 (ref)
Asp/Glu 30 13 1.5 (0.6–3.6) 30 13 2.2 (0.9–5.4)
Glu/Glu 10 3 1.3 (0.3–5.9) 1.5 (0.6–3.3)d 10 3 0.9 (0.2–4.5)
UGT2B7
His/His 31 9 1.0 (ref) 33 7 1.0 (ref)
His/Tyr 58 12 0.6 (0.2–1.7) 52 18 1.5 (0.5–4.5)
Tyr/Tyr 29 16 1.8 (0.6–5.2) 36 9 1.4 (0.4–4.5)
UGT2B15
Asp/Asp 20 10 1.0 (ref) 1.0 (ref) 25 5 1.0 (ref)
Asp/Tyr 61 19 0.5 (0.2–1.4) 59 21 1.3 (0.4–4.1)
Tyr/Tyr 37 8 0.4 (0.1–1.2) 0.5 (0.2–1.2)d 37 8 0.6 (0.2–2.4)
SULT1A1
Arg/Arg 49 19 1.0 (ref) 1.0 (ref) 52 16 1.0 (ref) 1.0 (ref)
Arg/His 50 13 0.6 (0.2–1.3) 50 13 0.9 (0.4–2.2)
His/His 19 5 0.6 (0.2–1.9) 0.6 (0.3–1.2)d 19 5 0.8 (0.2–2.6) 0.9 (0.4–2.0)d
ER, estrogen receptor; OR, odds ratio; PR, progesterone receptor. aAdjusted for age, menopausal status, age at menarche, number of 
pregnancies lasting at least 6 months (0, 1, 2, or 3 or more), parity/age at first birth (nulliparous, age at first birth 26 or less, age at first birth more 
than 26), weight change since age 18, race (Asian/Caucasian), smoking, and number of ovaries remaining. bGenotypes were also evaluated with 
the use of dichotomous variables ('any wild-type allele' [wild-type and heterozygous individuals] and 'any variant allele' [heterozygous and 
homozygous variant individuals]) when patterns suggested a dominant or recessive genotype effect. cP for trend = 0.03. dOR for combined group 
of heterozygous and homozygous variant individuals. eOR for combined group of wild type and heterozygous individuals.Breast Cancer Research    Vol 6 No 5    Sparks et al.
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were similar when the analyses were restricted to Cauca-
sians (data not shown). We did not observe that the rela-
tionship between any of the polymorphisms and circulating
sex hormone concentrations differed between tamoxifen
users and non-users (data not shown), but the small
number of individuals within each subgroup limited our abil-
ity to observe a difference.
Discussion
This study of female breast cancer patients had two aims:
first, to evaluate the risk of ER- or PR- tumors associated
with polymorphisms in specific UGT and SULT genes, and
second, to investigate whether plasma sex hormone con-
centrations varied within genotypes of these same genes.
To our knowledge this is the first study to investigate the
Table 3
Geometric mean estradiol (pg/ml), estrone (pg/ml), and testosterone (ng/dl) concentrations by genotype among postmenopausal 
Caucasian and Asian women with breast cancer in Washington state
Genotype Estradiol Estrone Testosterone
n Geometric 
meana 
(95% CI)
Percentage 
difference (P)
n Geometric 
meana 
(95% CI)
Percentage 
difference (P)
n Geometric 
meana 
(95% CI)
Percentage 
difference (P)
UGT1A1
(TA)6/(TA)6 (wt) 47 10.5
(9.1–12.1)
(Reference) 47 23.4
(20.9–26.3)
(Reference) 46 27.8
(24.9–31.0)
(Reference)
(TA)6/(TA)7 (het) 36 9.0
(7.3–11.2)
-14.1 (0.26) 36 21.1
(17.8–24.9)
-10.1 (0.31) 36 27.2
(23.8–31.2)
-1.9 (0.83)
(TA)7/(TA)7 (var) 4 16.6
(12.3–22.4)
+58.0 (0.01) 4 33.8
(19.9–57.4)
+44.1 (0.18) 4 29.9
(23.4–38.1)
+7.5 (0.60)
UGT2B4
Asp/Asp (wt) 51 9.5
(8.2–11.1)
(Reference) 51 22.3
(19.4–25.6)
(Reference) 50 27.3
(24.5–30.4)
(Reference)
Asp/Glu (het) 29 11.0
(8.9–13.5)
+15.3 (0.29) 29 23.4
(19.6–28.1)
+5.2 (0.67) 29 28.5
(24.6–33.0)
+4.3 (0.67)
Glu/Glu (var) 7 10.9
(7.3–16.2)
+14.4 (0.53) 7 24.3
(18.2–32.5)
+9.2 (0.59) 7 26.6
(19.9–35.4)
-2.8 (0.86)
UGT2B7
His/His (wt) 24 9.8
(7.5–12.8)
(Reference) 24 21.5
(17.8–26.0)
(Reference) 24 26.9
(23.3–31.0)
(Reference)
His/Tyr (het) 48 11.1
(9.6–12.9)
+13.3 (0.42) 48 24.0
(21.2–27.2)
+11.5 (0.34) 48 29.1
(26.2–32.3)
+8.2 (0.37)
Tyr/Tyr (var) 15 7.8
(5.6–10.7)
-20.9 (0.31) 15 21.3
(16.1–28.3)
-0.9 (0.96) 14 24.4
(19.4–30.7)
-9.2 (0.51)
UGT2B15
Asp/Asp (wt) 19 7.2
(5.6–9.3)
(Reference) 19 20.7
(16.1–26.5)
(Reference) 18 26.8
(21.3–33.6)
(Reference)
Asp/Tyr (het) 45 11.5
(9.9–13.3)
+58.7 (0.003) 45 23.7
(20.9–26.8)
+14.6 (0.34) 45 29.0
(26.1–32.2)
+8.3 (0.55)
Tyr/Tyr (var) 23 10.4
(8.2–13.1)
+43.7 (0.05) 23 23.1
(18.3–29.0)
+11.6 (0.53) 23 25.8
(22.0–30.3)
-3.6 (0.78)
SULT1A1
Arg/Arg (wt) 37 9.9
(7.8–12.6)
(Reference) 37 24.1
(20.0–29.2)
(Reference) 37 27.7
(23.9–32.0)
(Reference)
Arg/His (het) 38 9.8
(8.3–11.6)
-1.5 (0.93) 38 21.3
(18.6–24.3)
-12.0 (0.30) 37 25.2
(22.7–27.9)
-9.0 (0.32)
His/His (var) 12 11.6
(8.8–15.4)
+17.2 (0.42) 12 24.0
(19.3–29.9)
-0.6 (0.97) 12 36.5
(30.3–44.0)
+32.0 (0.03)
CI, confidence interval; het, heterozygous; var, homozygous variant; wt, wild-type. aGeometric mean estimates are for an individual with mean 
values of all covariates; adjusted for age, use of tamoxifen at the time of blood draw, smoking, alcohol use, percentage body fat, batch (estrone 
and estradiol only), number of ovaries remaining, and race (Asian/Caucasian).Available online http://breast-cancer-research.com/content/6/5/R488
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association between polymorphisms in the UGT2B4,
UGT2B7, and UGT2B15 genes and risk of an ER- or PR-
breast tumor.
There is increasing evidence that hormones are important
in the development of hormone-dependent and hormone-
independent breast cancer tumors [37-41]. Women with
ER- tumors have a worse prognosis and fewer treatment
modalities are available. We observed a reduced risk of an
ER- tumor in patients with the UGT1A1 (TA)7/(TA)7 geno-
type, and indications towards risk reduction with variants of
UGT2B15 and SULT1A1. The association between breast
tumor ER status and the number of TA repeats in the
UGT1A1 promoter region has previously been examined in
a case-control study of 200 African-American women with
breast cancer [14]. In that study, premenopausal women
with (TA)7 and (TA)8 'low-activity' alleles seemed to be at
higher risk for an ER- tumor than women with (TA)5 and
(TA)6 'high-activity' alleles (OR = 2.1, 95% CI 1.0–4.2)
[14]. This elevated risk did not extend to postmenopausal
women (OR = 0.8, 95% CI 0.3–1.9), which is consistent
with our results among a predominantly postmenopausal
population. Our finding of a somewhat reduced risk of an
ER- or PR- tumor in women with the SULT1A1 Arg/His and
His/His genotypes is consistent with the results of a study
of 337 breast cancer patients by Nowell and colleagues
[57]. Given that the hormonal milieu seems important for
the development of both hormone-dependent and hor-
mone-independent mammary tumors, our study, in conjunc-
tion with others, provides evidence that genotypes relevant
to the metabolism and excretion of sex hormones might
affect that milieu.
In a substudy of postmenopausal women at least 2 years
after diagnosis, we observed that plasma estradiol concen-
trations varied by UGT1A1 and UGT2B15 genotypes. The
UGT1A1 gene is involved in the glucuronidation of several
sex hormones, including 17β-estradiol [9,11]. Our finding
that breast cancer patients homozygous for the UGT1A1
variant (TA)7 allele seemed to have increased concentra-
tions of estradiol is consistent with the observation that the
variant allele has lower transcriptional activity in vitro than
the wild-type (TA)6 allele [12-14]. However, a study of 274
healthy postmenopausal women in the Nurses' Health
Study found that neither estrone nor estradiol concentra-
tion varied depending on UGT1A1  genotype [15]. Our
study was restricted to women with breast cancer, the
majority of whom were on tamoxifen therapy, which alters
estrogen levels, perhaps independently of these genetic
factors. Our findings should therefore be confirmed in addi-
tional populations of breast cancer patients and healthy
controls, to clarify the relationship between the UGT1A1
polymorphism and estradiol concentrations in both healthy
women and those with breast cancer.
Our finding that concentrations of estradiol were higher in
women with the UGT2B15 Tyr85 allele is surprising, given
that the UGT2B15 protein is not known to glucuronidate
estradiol [18,29]. Further, we did not observe that circulat-
ing testosterone concentrations varied greatly by
UGT2B15 genotype, despite the fact that UGT2B15 is
known to glucuronidate testosterone [18,29]. However,
this might be explained by the much higher glucuronidation
activity of UGT2B17 for testosterone than that of
UGT2B15 [18,58]. Also surprising was the finding that the
SULT1A1 His/His genotype was associated with elevated
testosterone concentrations, given that SULT1A1 does not
seem to conjugate testosterone [32]. It is possible that the
observed associations between sex hormone concentra-
tions and polymorphisms in UGT2B15 and SULT1A1 in
breast cancer patients are valid. However, they should be
viewed as possibly attributable to chance, because there
are conflicting biochemical data reported in the literature.
With regard to the UGT2B4 and UGT2B7 polymorphisms,
there was relatively little biochemical evidence to support
an a priori hypothesis about an association between these
polymorphisms and circulating sex hormone concentra-
tions or tumor receptor status. We therefore considered
these analyses to be 'hypothesis generating', in which any
observed association might elucidate the potential func-
tional relevance of these polymorphisms in vivo. We did not
find evidence that these polymorphisms were associated
with sex hormone concentrations or the risk of an ER- or PR-
breast cancer tumor. Our findings therefore support in vitro
data in which these sequence variations did not seem to
alter enzyme function [10,16,24,27].
Because genetic factors that might influence circulating
sex hormone concentrations in breast cancer patients
could influence response to treatment, it is important to
understand these associations in breast cancer patients.
The results of this study might serve as a starting point for
the formation and testing of additional hypotheses regard-
ing the potential association between polymorphisms in the
UGT2B4, UGT2B7, and UGT2B15 genes and serum hor-
mone concentrations or hormone receptor status. One
strength of the study is the investigation of several genetic
polymorphisms in genes relevant to sex hormone excretion
or regulation and the measurement of three sex hormones.
However, this study has several limitations. The small size
limited the statistical power in many of the analyses and
prohibited the evaluation of combined genotype effects.
Additionally, the coefficients of variation for the estrone and
estradiol assays were somewhat high, possibly preventing
us from detecting an association. Another limitation is that
we examined polymorphisms in only five genes whose pro-
tein products participate in sex hormone regulation; addi-
tional proteins involved in regulatory mechanisms thatBreast Cancer Research    Vol 6 No 5    Sparks et al.
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contribute to sex hormone concentrations in vivo could not
be considered as part of the study. As with any genetic
association study, the results must be interpreted in the
light of the possibility that observed associations might be
due to linkage disequilibrium between the examined poly-
morphism and a functional polymorphism that is the true
cause of the observed difference. Finally, because this
study involved mostly overweight women with breast can-
cer, most of whom were taking tamoxifen at the time of the
study, the observed associations between UGT and SULT
genotypes and circulating hormone levels might not be
generalizable to healthy women.
Conclusions
The results of this study of female breast cancer patients
indicate that the risk of ER- tumors varies by UGT1A1, and
possibly  UGT2B15  and  SULT1A1, genotype. Further,
there was some indication that plasma estradiol and testo-
sterone concentrations varied by UGT1A1, UGT2B15, or
SULT1A1 genotype. Owing to the preliminary nature of
these findings, they should be validated in a larger study
population.
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